S-1: ReShape Lifesciences Files for Potential $3.5 Million Common Stock Offering Amidst Strategic Shift

ReShape Lifesciences Inc. has filed a registration statement for a potential offering of up to $3.5 million in common stock, as the company navigates a proposed merger and asset sale.

Summary

• ReShape Lifesciences Inc. has filed a Form S-1 registration statement for a potential offering of up to $3.5 million in common stock.
• The offering is on a best-efforts basis, meaning there is no guarantee that the full amount will be raised.
• The company intends to use the net proceeds for general corporate purposes, including expenses related to a proposed merger with Vyome Therapeutics, Inc. and the sale of substantially all of its assets to Ninjour Health International Limited.
• A portion of the proceeds will be used to prepay a convertible note with Ascent Partners Fund LLC.
• The offering price will be determined at the time of pricing and may be at a discount to the current market price.
• The company has engaged a placement agent to solicit offers to purchase the securities.
• ReShape has recently undergone a reverse stock split of 1-for-58.
• The company is also in the process of a merger with Vyome Therapeutics, Inc. and the sale of substantially all of its assets to Ninjour Health International Limited.
• The company has a senior secured convertible note with Ascent Partners Fund LLC for $833,333.34.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments like new product approvals and cost reductions, the company faces significant financial challenges, including a history of losses, reliance on a best-efforts offering, and a complex merger and asset sale process. The risks outlined are substantial, leading to a below-average sentiment score.

Positives

• The company has a cost reduction plan that has led to approximately 41% lower operating expenses for the first nine months of 2024, compared to last year, excluding one-time costs.
• The company has prioritized investments, including marketing automation to support scalable lead acquisition, segmented consumer-centric messaging via an updated website for improved patient engagement, and a frictionless booking system with qualified providers.
• The company has received FDA approval for the Lap-Band 2.0 FLEX system.
• The company has an OEM partnership with Biorad Medisys to support the relaunch of the Obalon Balloon system.

Negatives

• The offering is on a best-efforts basis, meaning there is no guarantee that the full amount will be raised.
• The company will use 50% of the proceeds to prepay a convertible note with Ascent Partners Fund LLC.
• The company has a senior secured convertible note with Ascent Partners Fund LLC for $833,333.34.
• The company has a history of losses and negative cash flows.
• The company is dependent on the closing of the merger and asset sale to continue operations.

Risks

• The sale or issuance of common stock to Ascent may cause dilution and the sale of the shares of common stock acquired by Ascent, or the perception that such sales may occur, could cause the price of our common stock to fall.
• Ascent will pay less than the then-prevailing market price for our common stock, which could cause the price of our common stock to decline.
• The Note is fully secured by collateral of ReShape and our subsidiaries and Ascent, as our senior secured lender, may exercise its right in the event of default.
• We may require additional financing to sustain our operations, without which we may not be able to continue operations, and the terms of subsequent financings may adversely impact our stockholders.
• Our management will have broad discretion over the use of the net proceeds from our sale of shares of common stock to Ascent, and you may not agree with how we use the proceeds, and the proceeds may not be invested successfully.
• It is not possible to predict the actual number of shares we will sell under the Equity Purchase Agreement to Ascent or the actual gross proceeds resulting from those sales.
• Investors who buy shares at different times will likely pay different prices.
• Our commitment to issue shares of our common stock pursuant to the terms of the Equity Purchase Agreement could encourage short sales by third parties, which could contribute to the future decline of our stock price.
• The Merger may not be consummated unless important conditions are satisfied or waived and there can be no assurance that the Merger will be consummated.
• If we are unable to either substantially improve our operating results or obtain additional financing, we may be unable to continue as a going concern.
• We may be unable to attract and retain management and other personnel we need to succeed.
• We cannot assure you that we will ever generate substantial revenue or be profitable.
• Our efforts to increase revenue from our Lap-Band System, Lap-Band 2.0 System, and commercialize our DBSN device and expanded line of bariatric surgical accessories, including ReShape Calibration Tubes, may not succeed or may encounter delays which could significantly harm our ability to generate revenue.
• We may not be able to obtain required regulatory approvals for our DBSN device in a cost-effective manner or at all, which could adversely affect our business and operating results.
• If we are unable to obtain or maintain intellectual property rights relating to our technology and neuroblocking therapy, the commercial value of our technology and any future products will be adversely affected and our competitive position will be harmed.
• The trading price of our common stock has been volatile and is likely to be volatile in the future.
• Sales of a substantial number of shares of our common stock in the public market by existing stockholders, or the perception that they may occur, could cause our stock price to decline.
• We have a significant number of outstanding warrants, which may cause significant dilution to our stockholders, have a material adverse impact on the market price of our common stock and make it more difficult for us to raise funds through future equity offerings.
• While the ReShape Asset Sale is pending, it creates unknown impacts on ReShapes future which could materially and adversely affect its business, financial condition and results of operations.
• The failure to consummate the ReShape Asset Sale may materially and adversely affect ReShapes business, financial condition and results of operations.
• The Merger may be consummated despite the ReShape Asset Sale not closing under certain circumstances.
• Management will have broad discretion as to the use of the net proceeds from this offering, and we may not use these proceeds effectively.
• This is a best efforts offering, and no minimum number or dollar amount of securities is required to be sold, and we may not raise the maximum amount we are offering.

Future Outlook

The company intends to use the net proceeds from this offering for general corporate purposes, including expenses related to the proposed merger with Vyome Therapeutics, Inc. and the sale of substantially all of its assets to Ninjour Health International Limited. The combined company intends to focus on Vyomes business of advancing the development of its immuno-inflammatory assets and on identifying additional opportunities between the world-class Indian innovation corridor and the U.S. market.

Management Comments

• Under this new leadership, our company has pivoted its business strategy with the intent of helping to ensure growth and profitability.
• This first growth pillar remains, in our companys opinion, paramount for ReShape to deliver shareholder value and, ultimately, profitability.
• Based on customer feedback, Lap-Band 2.0 will allow us to engage new surgeons and reengage many of those who have used the Lap-Band, historically.

Industry Context

The document highlights the competitive landscape in the weight loss solutions market, noting the impact of GLP-1 receptor agonists like Wegovy, Ozempic, and Zepbound. It also emphasizes the company's commitment to providing a range of solutions across the weight loss care continuum, including minimally invasive surgical options and combination therapies.

Comparison to Industry Standards

• The document mentions competitors in the obesity treatment field, including Allergan, Boston Scientific, LivaNova PLC, Johnson & Johnson, Medtronic or St. Jude Medical, many of which have significantly greater financial resources and expertise.
• The document also notes that smaller or early-stage companies may also prove to be significant competitors, particularly if they pursue competing solutions through collaborative arrangements with large and established companies.
• The document highlights the competitive landscape in the weight loss solutions market, noting the impact of GLP-1 receptor agonists like Wegovy, Ozempic, and Zepbound.

Stakeholder Impact

• Shareholders face potential dilution from the stock offering and the merger.
• Employees may be affected by the ongoing cost reduction plan and reorganization.
• Customers may benefit from the company's expanded product portfolio and services.
• Suppliers may be impacted by the company's strategic shift and potential changes in operations.
• Creditors may be affected by the company's debt obligations and potential restructuring.

Next Steps

• The company will seek to complete the merger with Vyome Therapeutics, Inc. and the sale of substantially all of its assets to Ninjour Health International Limited.
• The company will continue to develop and commercialize its product portfolio, including the Lap-Band 2.0 FLEX system and the Obalon Balloon system.
• The company will continue to develop the DBSN device for type 2 diabetes.
• The company will seek to obtain regulatory approvals for its products in various markets.

Key Dates

Keywords

common stock offering, merger, asset sale, convertible note, Lap-Band, Obalon Balloon, DBSN device, weight loss solutions, bariatric surgery, Ascent Partners Fund LLC